Literature DB >> 15704035

Heart failure in pediatric patients.

M Hoch1, H Netz.   

Abstract

Paradigms in understanding heart failure have changed as the knowledge of pathophysiology and its molecular basis has deepened. In the chronic compensated state of heart failure recent research has focussed on the body's regulatory mechanisms. Today heart failure is understood as a complex interplay of hemodynamic and neurohormonal factors. In pediatrics a large variety of heterogeneous conditions cause heart failure. Some require special therapeutic approaches such as the infusion of prostaglandin for ductal patency, the careful maintenance of balance between systemic and pulmonary circulations or operative treatment. In newborns with critical congenital lesions and in patients in the postoperative period management of acute heart failure becomes important. Chronic heart failure as it is understood today is present in patients with cardiomyopathies and in an increasing number of pediatric patients after palliative surgery. In heart failure due to left-to-right shunts a similar activation of compensatory neurohormonal mechanisms as in adults with chronic heart failure was found. In small clinical trials treatment of these activated compensatory mechanisms with angiotensin-converting enzyme inhibitors and beta-blockers showed beneficial effects in pediatric patients. However large clinical multicenter trials as performed in the adult population should be conducted.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15704035     DOI: 10.1055/s-2004-830452

Source DB:  PubMed          Journal:  Thorac Cardiovasc Surg        ISSN: 0171-6425            Impact factor:   1.827


  5 in total

Review 1.  Future pharmacologic agents for treatment of heart failure in children.

Authors:  Brady S Moffett; Anthony C Chang
Journal:  Pediatr Cardiol       Date:  2006-08-23       Impact factor: 1.655

2.  Captopril induced reversible acute renal failure in a premature neonate with double outlet right ventricle and congestive heart failure.

Authors:  Lin-Hua Tan; Li-Zhong Du; Michael R Carr; Julia K Kuzin; Brady S Moffett; Anthony C Chang
Journal:  World J Pediatr       Date:  2010-12-30       Impact factor: 2.764

3.  Model-based approaches for ivabradine development in paediatric population, part II: PK and PK/PD assessment.

Authors:  Sophie Peigné; Sylvain Fouliard; Sophie Decourcelle; Marylore Chenel
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-11-14       Impact factor: 2.745

4.  Variations in captopril formulations used to treat children with heart failure: a survey in the United kingdom.

Authors:  Hussain Mulla; Magdi Tofeig; Frances Bu'Lock; Nilesh Samani; Hitesh C Pandya
Journal:  Arch Dis Child       Date:  2007-03-15       Impact factor: 3.791

5.  Beta-adrenergic receptor antagonists and chronic heart failure in children.

Authors:  Sylvie Di Filippo
Journal:  Ther Clin Risk Manag       Date:  2007-10       Impact factor: 2.423

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.